NCT02692105Active, not recruitingPhase 3
Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer
A Phase III Randomized Pilot Study of Low Dose Rate Compared to High Dose Rate Prostate Brachytherapy for Favourable Risk and Low Tier Intermediate Risk Prostate Cancer
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
This study will offer men with intermediate risk prostate cancer who are suitable for, and interested in, prostate brachytherapy, the opportunity to be randomized between low dose rate (LDR) brachytherapy using permanent implantation of radioactive seeds (the current standard of care in BC) and high dose rate (HDR) or temporary brachytherapy which is also available as a standard of care in BC but only when used as a boost in addition with external beam radiotherapy. In addition, men will be offered the opportunity for testing the aggressiveness of their cancer using Cell Cycle Progression Gene Profile.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 17 Feb 2016
- Start date
- May 2016
- Primary completion date
- Apr 2021
- Lead sponsor
- British Columbia Cancer Agency
- Diseases
- Prostate cancer
- NCT number
- NCT02692105
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 60
- From May 2016 to the primary completion date, Apr 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radical surgery for carcinoma of the prostate,
- Prior pelvic radiation
- Prior chemotherapy for prostate cancer,
- Prior TURP or cryosurgery of the prostate
Other
- Claustrophobic or unable to undergo MRI
Who the study is looking for
- Clinical stage T1c-T2b, PSA \< 20, Gleason \< 8
- ECOG 0-1
- Low tier intermediate-risk prostate cancer is defined by;
- o a single NCCN intermediate risk factor (either Gleason 7(3+4) and PSA \< 10 ng/ml OR Gleason 6 and PSA 10-20 ng/ml)
- Extensive favorable-risk disease is defined as:
- clinical stage T1c-T2a
- PSA \< 10
- Gleason 6
- ≥ 50% of biopsy cores containing cancer
- PSA density \> 0.2 ng/cc
- Selected intermediate risk patients not defined above
- \- T1c/T2a
- \- PSA \< 10
- -Gleason 4+3
- -\< 33% of cores involved
- -Max tumour length in any core 10 mm
- No androgen deprivation therapy (ADT)
- Prostate volume by TRUS ≤ 60 cc.
- Not eligible for, or accepting of, active surveillance according to NCCN guidelines.
- Signed study specific informed consent.
Age in the registry: 40 years to 80 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| British Columbia Cancer Agency Center for the Southern Interior Coordinator of this site? Confirm its status | Kelowna | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.